Unprofitable companies can burn through cash quickly, leaving investors exposed if they fail to turn things around. Without a clear path to profitability, these businesses risk running out of capital or relying on dilutive fundraising.
Unprofitable companies face an uphill battle, but not all are created equal. Luckily for you, StockStory is here to separate the promising ones from the weak. That said, here is one unprofitable company investing heavily to secure market share and two that may never reach the Promised Land.
Two Stocks to Sell:
Lucid (LCID)
Trailing 12-Month GAAP Operating Margin: -271%
Founded by a former Tesla Vice President, Lucid Group (NASDAQ: LCID) designs, manufactures, and sells luxury electric vehicles with long-range capabilities.
Why Is LCID Not Exciting?
- Negative 136% gross margin means it loses money on every sale and must pivot or scale quickly to survive
- Cash-burning history makes us doubt the long-term viability of its business model
- Depletion of cash reserves could lead to a fundraising event that triggers shareholder dilution
Lucid is trading at $6.10 per share, or 0.8x forward price-to-sales. Check out our free in-depth research report to learn more about why LCID doesn’t pass our bar.
10x Genomics (TXG)
Trailing 12-Month GAAP Operating Margin: -6.1%
Founded in 2012 by scientists seeking to overcome limitations in traditional biological research methods, 10x Genomics (NASDAQ: TXG) develops instruments, consumables, and software that enable researchers to analyze biological systems at single-cell resolution and spatial context.
Why Should You Dump TXG?
- Sales trends were unexciting over the last two years as its 1.1% annual growth was below the typical healthcare company
- Revenue base of $638.8 million puts it at a disadvantage compared to larger competitors exhibiting economies of scale
- Push for growth has led to negative returns on capital, signaling value destruction
At $39.08 per share, 10x Genomics trades at 8x forward price-to-sales. Dive into our free research report to see why there are better opportunities than TXG.
One Stock to Watch:
iRhythm (IRTC)
Trailing 12-Month GAAP Operating Margin: -5.2%
Pioneering the shift from bulky, short-term heart monitors to sleek, wire-free patches, iRhythm Technologies (NASDAQ: IRTC) provides wearable cardiac monitoring devices and AI-powered analysis services that help physicians detect and diagnose heart rhythm disorders.
Why Does IRTC Catch Our Eye?
- Annual revenue growth of 23.9% over the last two years was superb and indicates its market share increased during this cycle
- Additional sales over the last five years increased its profitability as the 27.5% annual growth in its earnings per share outpaced its revenue
- Free cash flow profile has moved into positive territory over the last five years, indicating the company has achieved financial self-sustainability
iRhythm’s stock price of $126.48 implies a valuation ratio of 360.7x forward P/E. Is now the right time to buy? Find out in our full research report, it’s free.
High-Quality Stocks for All Market Conditions
ONE MORE THING: Top 6 Stocks for This Week. This market is separating quality stocks from expensive ones fast. AI is taking down whole sectors with no warning. In a rotation this fast, you need more than a list of good companies.
Our AI system flagged Palantir before it ran 1,662%. AppLovin before it ran 753%. Nvidia before it ran 1,178%. Each week it produces 6 new names that pass the same tests. Get Our Top 6 Stocks for Free HERE.
Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,326% between June 2020 and June 2025) as well as under-the-radar businesses like the once-micro-cap company Tecnoglass (+1,754% five-year return). Find your next big winner with StockStory today.
